MetaVia MTVA
NASDAQ MTVA
$1.46 +0.02 (+1.39%)
At close: Aug 21, 2026 · 4:00 PM EDT

MetaVia (MTVA) Total Non-Current Liabilities (2015 - 2023)

MetaVia's (MTVA) quarterly Total Non-Current Liabilities came in at $3.0 million in Q2 2023, up 95.83% on a QoQ basis from $1.5 million in Q1 2023.

MetaVia (MTVA) Total Non-Current Liabilities (2015 - 2023) Analysis & Trends

MetaVia (MTVA) has 9 years of Total Non-Current Liabilities data on file, last reported at $3.0 million in Q2 2023.

  • Quarterly Total Non-Current Liabilities changed N/A year-over-year to $3.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $3.0 million (changed N/A YoY) and the FY2022 annual result came in at $988000.0, down 55.13% from the prior year.
  • Total Non-Current Liabilities rose to $3.0 million in Q2 2023, from $1.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $3.8 million in Q4 2020 to a low of $988000.0 in Q4 2022.
  • A 5-year average of $2.3 million and a median of $2.2 million in 2019 frame the typical range for Total Non-Current Liabilities.
  • The widest YoY moves for Total Non-Current Liabilities: up 506.13% in 2019, down 87.79% in 2019.
  • Tracing MTVA's Total Non-Current Liabilities over 5 years: stood at $2.2 million in 2019, then jumped by 73.02% to $3.8 million in 2020, then plunged by 41.51% to $2.2 million in 2021, then plunged by 55.13% to $988000.0 in 2022, then surged by 204.45% to $3.0 million in 2023.
  • The last three Total Non-Current Liabilities figures came in at $3.0 million (Q2 2023), $1.5 million (Q1 2023), and $988000.0 (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 3.92 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 1.88 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 4.20 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 724.15 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 1.17 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 9.32 Bn
10 MetaVia 8.72 Mn -3.92 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 3.01 Mn
Mar 31, 2023 1.54 Mn
Dec 31, 2022 988,000.00
Dec 31, 2021 2.20 Mn
Dec 31, 2020 3.77 Mn
Dec 31, 2019 2.18 Mn
Sep 30, 2019 3.07 Mn
Jun 30, 2019 2.05 Mn
Mar 31, 2019 1.71 Mn
Dec 31, 2018 359,000.00
Sep 30, 2018 14.02 Mn
Jun 30, 2018 13.76 Mn
Mar 31, 2018 14.02 Mn
Dec 31, 2017 15.07 Mn
Sep 30, 2017 16.26 Mn
Jun 30, 2017 5.27 Mn
Mar 31, 2017 4.54 Mn
Dec 31, 2016 4.12 Mn
Dec 31, 2015 8.92 Mn